Stratus Therapeutics
Apurva Dhupkar has a diverse work experience history. In 2014, they worked as a Summer Intern at the Indian Institute of Science. From 2017 to 2021, they worked as a Clinical Laboratory Scientist at Biosciences Clinic, where they were involved in the manufacturing process of extracting mesenchymal stem cells from adipose tissue for various aesthetic treatments. In 2021, they became a Research Assistant at the University of Southern California, volunteering at the Jadhav lab and assisting in laboratory experiments related to epigenetic changes. In 2022, they joined Jounce Therapeutics, Inc. as a Senior Research Associate, before moving on to their current role as an Associate Scientist at Garuda Therapeutics in 2023.
Apurva Dhupkar holds a Master's degree in Stem cell biology and Regenerative Medicine from the Keck School of Medicine of the University of Southern California, obtained from 2021 to 2022. They also possess a Bachelor of Science (B.Sc.) degree in Microbiology, General, acquired from Fergusson College between 2013 and 2015. Additionally, Apurva Dhupkar pursued a Master's degree in Genetics and Molecular Biology at Manipal University, Dubai, from 2015 to 2017.
This person is not in the org chart
Stratus Therapeutics
4 followers
Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution.